

# **Supplementary Material**

## **Search strategy (August 31, 2021)**

### **Search strategy for Embase (934 items)**

1. 'coronavirus disease 2019'/exp OR 'Severe acute respiratory syndrome coronavirus 2'/exp OR (COVID-19 OR SARS-CoV-2):ti,ab
2. vaccine/exp OR vaccination/exp OR immunization/exp OR (vaccin\* OR immuniz\*):ti,ab
3. (variant\* OR B.1.1.7 OR B.1.351 OR P.1 OR B.1.617.2):ti,ab
4. #1 AND #2 AND #3

### **Search strategy for Pubmed (1203 items)**

1. COVID-19[Mesh] OR SARS-CoV-2[Mesh] OR "COVID-19 Vaccines"[Mesh] OR COVID-19[Title/Abstract] OR SARS-CoV-2[Title/Abstract]
2. vaccines[Mesh] OR vaccination[Mesh] OR immunization[Mesh] OR vaccin\*[Title/Abstract] OR immuniz\*[Title/Abstract]
3. variant\*[Title/Abstract] OR B.1.1.7[Title/Abstract] OR B.1.351[Title/Abstract] OR P.1[Title/Abstract] OR B.1.617.2[Title/Abstract]
4. #1 OR #2 OR #3

### **Search strategy for Cochrane Library (23 items)**

1. [mh COVID-19]
2. [mh SARS-CoV-2]
3. COVID-19:ti,ab
4. SARS-CoV-2:ti,ab
5. #1 OR #2 OR #3 OR #4
6. [mh vaccines]
7. [mh vaccination]
8. [mh immunization]
9. vaccin\*:ti,ab
10. immuniz\*:ti,ab
11. #6 OR #7 OR #8 OR #9 OR #10
12. (variant\* OR B.1.1.7 OR B.1.351 OR P.1 OR B.1.617.2):ti,ab
13. #5 AND #11 AND #12


### **Search strategy for Clinicaltrial.gov (66 items)**

(vaccines OR vaccine OR vaccination OR immunization) AND (variant OR variants) AND (COVID-19 OR SARS-CoV-2)

### **Search strategy for medRxiv (596 items)**

(vaccin\*) AND (variant\*) AND (COVID-19 OR SARS-CoV-2) AND (Efficacy OR Effectiveness)

## Supplementary Figure



**Supplementary Figure 1.** Flow chart of literature search and study selection.

## Supplementary Tables

**Supplementary Table 1.** Risk of bias for included RCTs

Study (First author)	Randomization process	Deviations from intended interventions	Missing data	outcome	Measurement of the outcome	Selection of the reported result	Overall bias
Heath	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns	Some concerns
Emary	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns	Some concerns
Shinde	Low	Low	Some concerns	Low	Some concerns	Some concerns	Some concerns
Madhi	Low	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns
Sadoff	Low	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
Thomas (preprint)	Low	Some concerns	Low	Low	Low	Some concerns	Some concerns
Ella (preprint)	Low	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns

**Supplementary Table 2.** Risk of bias for included cohort studies

	Selection					Comparability	Exposure			Total score	Quality
	Item 1	Item 2	Item 3	Item 4	Item 5		Item 6	Item 7	Item 7		
Hall	1	1	1	1	1		1	1	1	8	Good
Haas	1	1	1	0	1		1	1	1	7	Good
Lumley	1	1	1	0	1		1	1	1	7	Good
Williams	0	1	1	0	0		0	1	1	4	Moderate
Nanduri	1	1	1	0	1		1	1	1	7	Good
Fowlkes	0	1	1	0	1		0	1	1	5	Moderate
Puranik (preprint)	1	1	1	0	2		1	1	1	8	Good
Lefèvre (preprint)	0	1	1	0	1		1	1	1	6	Moderate
Dagan	1	1	1	0	2		1	1	1	8	Good
Pouwels (preprint)	1	1	1	0	2		1	1	1	8	Good

Item 1: Representativeness of the exposed cohort.

Item 2: Selection of the non-exposed cohort.

Item 3: Ascertainment of exposure.

Item 4: Demonstration that outcome of interest was not present at start of study.

Item 5: Comparability of cohorts on the basis of the design or analysis.

Item 6: Assessment of outcome.

Item 7: Was follow up long enough for outcomes to occur.

Item 8: Adequacy of follow up of cohorts.

**Supplementary Table 3.** Risk of bias for included case-control studies

	Selection					Comparability	Exposure			Total score	Quality
	Item 1	Item 2	Item 3	Item 4	Item 5		Item 6	Item 7	Item 7		
Charmet	1	1	1	1	1		1	0	1	7	Good
Nasreen (preprint)	1	1	1	1	1		1	1	1	8	Good
Skowronski	1	0	1	1	1		1	1	1	7	Good
Hitchings (preprint)	1	0	1	1	0		1	1	1	6	Moderate
Ranzani	1	0	1	1	2		1	1	1	8	Good
Lopez Bernal	1	1	1	1	2		1	1	1	9	Good
Tang (preprint)	1	1	1	1	2		1	1	1	9	Good
Li	1	0	1	1	1		1	1	1	7	Good
Abu-Raddad	1	1	1	1	2		1	1	1	9	Good
Sheikh	1	0	1	1	0		1	1	1	6	Moderate
Chemaitlely	1	1	1	1	2		1	1	1	9	Good
Bernal	1	0	1	1	1		1	1	1	7	Good
Chung	1	1	1	1	1		1	1	1	8	Good
Carazo	1	0	1	1	1		1	1	1	7	Good
Chemaitlely (preprint)	1	1	1	1	2		1	1	1	9	Good
Pramod (preprint)	1	0	1	1	1		1	1	0	6	Moderate

Item 1: Is the case definition adequate?

Item 2: Representativeness of the cases.

Item 3: Selection of controls.

Item 4: Definition of controls.

Item 5: Comparability of cases and controls on the basis of the design or analysis.

Item 6: Ascertainment of exposure.

Item 7: Same method of ascertainment for cases and controls.

Item 8: Non-Response Rate.

**Supplementary Table 4.** VE of COVID-19 vaccines against B.1.1.7 (Alpha) variant

First author/Country	Study design	Vaccine/control or Cases/controls	Participants	Age (years)	Vaccine	Outcomes	Day_1	VE% of one dose (95% CI)	Day_2	VE% of two doses (95% CI)	Variants
Heath/UK	RCT	7,020/7,020	GP	18-84	NVX-CoV2373	Symptomatic	NA	NA	7	86.3 (71.3–93.5)	Alpha
Emary/UK	RCT	4,244/4,290	GP	≥18	ChAdOx1	Symptomatic	NA	NA	14	70.4 (43.6–84.5)	Alpha
Hall/UK	Cohort	8,203/15,121	HCWs	≥18	BNT162b2	All infections	21	72.0 (58.0–86.0)	7	86.0 (76.0–97.0)	Alpha (>50%)
Haas/Israel	Cohort	4,714,932/1,823,979	GP	≥16	BNT162b2	All infections	NA	NA	7	96.5 (96.3–96.8)	Alpha (95%)
Lumley/UK	Cohort	10,651/10,513	HCWs	39 (30-50) <sup>1</sup>	BNT162b2/ ChAdOx1	All infections	14	21.0 (-3.0–39.0)	14	82.0 (27.0–95.0)	Alpha (51%)
Dagan/Israel	Cohort	596,618/596,618	GP	≥16	BNT162b2	All infections	14-21	46.0 (40.0–51.0)	7	92.0 (88.0–95.0)	Alpha (80%)
Pouwels/UK <i>_preprint</i>	Cohort	384,543 (total)	GP	≥18	BNT162b2	All infections	21	59.0 (52.0–65.0)	14	78.0 (68.0–84.0)	Alpha (dominant)
			GP	≥18	ChAdOx1	All infections	21	63.0 (55.0–69.0)	14	79.0 (56.0–90.0)	Alpha
Lopez Bernal/UK	TNCC	9,682/171,834	GP	≥16	BNT162b2/ ChAdOx1	Symptomatic	21	48.7 (45.5–51.7)	14	87.5 (85.1–89.5)	Alpha
		7,812/120,761	GP	≥16	BNT162b2	Symptomatic	21	47.5 (41.6–52.8)	14	93.7 (91.6–95.3)	Alpha
		9,183/147,444	GP	≥16	ChAdOx1	Symptomatic	21	48.7 (45.2–51.9)	14	74.5 (68.4–79.4)	Alpha
Abu-Raddad/Qatar	TNCC	19,017/19,432	GP	33 (22-40) <sup>1</sup>	BNT162b2	All infections	0	29.5 (22.9–35.5)	14	89.5 (85.9–92.3)	Alpha
Bernal/UK	TNCC	3,034/9,487	Older	≥70	BNT162b2	Symptomatic	21	36.2 (23.7–46.6)	14	90.0 (84.0–94.0)	Alpha
Chemaiteily/Qatar	TNCC	23,904/23,951	GP	32 (25-39) <sup>1</sup>	mRNA-1273	All infections	14	88.1 (83.7–91.5)	14	100 (91.8–100)	Alpha
Charmet/France <i>rol</i>	Case-cont	31,313/3,644	GP	≥20	BNT162b2/ mRNA-1273	All infections	NA	NA	7	86.0 (81.0–90.0)	Alpha
Skowronski/Canada	TNCC	303/10,388	Older	≥70	BNT162b2/ mRNA-1273	All infections	21	67.0 (57.0–75.0)	NA	NA	Alpha
Sheikh/UK	TNCC	6,205/187,318	GP	NA	BNT162b2	All infections	28	38.0 (29.0–45.0)	14	92.0 (90.0–93.0)	Alpha
		6,884/203,579	GP	NA	ChAdOx1	All infections	28	37.0 (32.0–42.0)	14	73.0 (66.0–78.0)	Alpha
Carazo/Canada	TNCC	901/46,862	HCWs	18-74	BNT162b2/ mRNA-1273	All infections	14	60.0 (53.6–65.5)	7	92.6 (87.1–95.8)	Alpha

Chung/Canada	TNCC	12,582/259,986	GP	$\geq 16$	BNT162b2/ mRNA-1273	Symptomatic	14	61.0 (56.0–66.0)	7	90.0 (85.0–94.0)	Alpha
Chemaiteily/Qatar <i>_preprint</i>	TNCC	1,888/1,888	GP	32 (23-39) <sup>1</sup>	BNT162b2	All infections	14	54.9 (28.0–72.4)	0-4 weeks	67.8 (57.1–76.1)	Alpha
Nasreen/Canada <i>_preprint</i>	TNCC	368,323/51,540	GP	$\geq 16$	BNT162b2	Symptomatic	21	69.0 (67.0–71.0)	14	89.0 (87.0–91.0)	Alpha
			GP	$\geq 16$	mRNA-1273	Symptomatic	21	84.0 (80.0–86.0)	14	91.0 (84.0–95.0)	Alpha
			GP	$\geq 16$	ChAdOx1	Symptomatic	21	72.0 (68.0–76.0)	14	75.0 (-98.0–97.0)	Alpha

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; TNCC, test-negative case-control; GP, general population; Day\_1, days after the 1<sup>st</sup> dose; Day\_2, days after the 2<sup>nd</sup> dose; RCT, randomized controlled trial; CI, confidence interval.

<sup>1</sup> Median age (interquartile range)

**Supplementary Table 5. VE of COVID-19 vaccines against B.1.351 (Beta) and P.1 (Gamma) variant**

First author/Country	Study design	Vaccine/control or Cases/controls	Participants	Age (years)	Vaccine	Outcomes	Day_1	VE% of one dose (95% CI)	Day_2	VE% of two doses (95% CI)	Variants
Shinde/South Africa	RCT	1,357/1,327	GP	18-84	NVX-CoV2373	Symptomatic	NA	NA	NA	51.1 (-0.6–76.2)	Beta
Madhi/South Africa	RCT	750/714	GP	18-65	ChAdOx1	Symptomatic	NA	NA	NA	10.4 (-76.8–54.8)	Beta
Sadoff/South Africa	RCT	2,473/2,496	GP	≥18	Ad26.COV2.S	Symptomatic	14	52.0 (30.3–67.4)	NA	NA	Beta
	RCT	2,473/2,496	GP	≥18	Ad26.COV2.S	Symptomatic	28	64.0 (41.2–78.7)	NA	NA	Beta
Thomas/South Africa_ <i>preprint</i>	RCT	291/276	GP	≥16	BNT162b2	All infections	NA	NA	7	100 (53.5–100)	Beta
Abu-Raddad/Qatar	TNCC	21,685/22,204	GP	33 (22-40) <sup>1</sup>	BNT162b2	All infections	0	16.9 (10.4–23.0)	14	75.0 (70.5–78.9)	Beta
Chemaiteily/Qatar	TNCC	48,297/48,456	GP	32 (25-39) <sup>1</sup>	mRNA-1273	All infections	14	61.3 (56.5–65.5)	14	96.4 (91.9–98.7)	Beta
Charmet/France	Case-cont rol	2,550/3,644	GP	≥20	BNT162b2/ mRNA-1273	All infections	NA	NA	7	77.0 (63.0–86.0)	Beta (95.1%)
Lefèvre/France	Cohort	338/40	LTCH	89 (83-92) <sup>1</sup>	BNT162b2	All infections	14	55.0 (13.0–76.0)	7	49.0 (14.0–69.0)	Beta
Chemaiteily/Qatar_ <i>p reprint</i>	TNCC	3,277/3,277	GP	32 (23-39) <sup>1</sup>	BNT162b2	All infections	14	26.1 (0.0-45.7)	0-4 weeks	74.3 (68.5-79.2)	Beta
Williams/Canada	Cohort	48/12	Residents of LTCH	NA	mRNA-1273	All infections	NA	NA	14	52.5 (26.9–69.1)	Gamma
		43/40	Staff of LTCH	NA	mRNA-1273	All infections	NA	NA	14	66.2 (2.3–88.3)	Gamma
Ranzani/Brazil	TNCC	26,433/17,622	Older	≥70	CoronaVac	Symptomatic	14	12.5 (3.7–20.6)	14	46.8 (38.7–53.8)	Gamma
Skowronski/Canada	TNCC	180/10,388	Older	≥70	BNT162b2/ mRNA-1273	All infections	21	61.0 (45.0–72.0)	NA	NA	Gamma
Hitchings/Brazil_ <i>preprint</i>	TNCC	418/418	HCWs	≥18	CoronaVac	Symptomatic	NA	NA	14	36.8 (-54.9–74.2)	Gamma (66%)
Chung/ Canada	TNCC	NA/259,986	GP	≥16	BNT162b2/ mRNA-1273	Symptomatic	14	43.0 (22.0–59.0)	7	88.0 (61.0–96.0)	Beta/Gamma

Nasreen/Canada <i>pre print</i>	TNCC	3,005/351,540	GP	$\geq 16$	BNT162b2	Symptomatic	21	65.0 (56.0–71.0)	14	85.0 (70.0–93.0)	Beta/Gamma
			GP	$\geq 16$	mRNA-1273	Symptomatic	21	78.0 (60.0–88.0)	NA	NA	Beta/Gamma
			GP	$\geq 16$	ChAdOx1	Symptomatic	21	50.0 (27.0–66.0)	NA	NA	Beta/Gamma

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; TNCC, test-negative case-control; LTCH, long term care homes; GP, general population; Day\_1, days after the 1<sup>st</sup> dose; Day\_2, days after the 2<sup>nd</sup> dose; RCT, randomized controlled trial; CI, confidence interval.

<sup>1</sup> Median age (interquartile range)

**Supplementary Table 6. VE of COVID-19 vaccines against B.1.617.2 (Delta) variant**

First author/ Country	Study design	Vaccine/control Cases/controls	or (years)	Participants	Age	Vaccine	Outcomes	Day_1	VE% of one dose (95% CI)	Day_2	VE% of two doses (95% CI)	Variants
Ella/India/_preprint	RCT	8,471/8,502	GP	18-98	BBV152	Symptomatic	NA	NA	14	65.2 (33.1–83.0)	Delta	
Lopez Bernal/UK	TNCC	5,876/171,834	GP	≥16	BNT162b2/ ChAdOx1	Symptomatic	21	30.7 (25.2–35.7)	14	79.6 (76.7–82.1)	Delta	
		4,302/120,761	GP	≥16	BNT162b2	Symptomatic	21	35.6 (22.7–46.4)	14	88.0 (85.3–90.1)	Delta	
		5,617/147,444	GP	≥16	ChAdOx1	Symptomatic	21	30.0 (24.3–35.3)	14	67.0 (61.3–71.8)	Delta	
Li/China	TNCC	74/292	GP	18-59	CoronaVac/ CNBG	All infections	14	13.8 (-60.2–54.8)	14	59.0 (16.0–81.6)	Delta	
Nanduri/US	Cohort	5,011,746/953,861	Nursing home	NA	BNT162b2/ mRNA-1273	All infections	NA	NA	14	53.1 (49.1–56.7)	Delta	
		3,248,732/953,861		NA	BNT162b2	All infections	NA	NA	14	52.4 (48.0–56.4)	Delta	
		1,763,014/953,861		NA	mRNA-1273	All infections	NA	NA	14	50.6 (45.0–55.7)	Delta	
Fowlkes/US	Cohort	2,352/488	Frontline workers	NA	mRNA-1273/ BNT162b2	All infections	NA	NA	14	66.0 (26.0–84.0)	Delta	
Sheikh/UK	TNCC	4,043/185,156	GP	NA	BNT162b2	All infections	28	30.0 (17.0–41.0)	14	79.0 (75.0–82.0)	Delta	
		4,679/201,374	GP	NA	ChAdOx1	All infections	28	18.0 (9.0–25.0)	14	60.0 (53.0–66.0)	Delta	
Puranik/US_preprint	Cohort	21,079/24,444	GP	≥18	mRNA-1273	All infections	NA	NA	14	76.0 (58.0–87.0)	Delta (70%)	
		21,946/24,444	GP	≥18	BNT162b2	All infections	NA	NA	14	42.0 (13.0–62.0)	Delta (70%)	
Chemaitelly/Qatar _preprint	TNCC	1,935/1,935	GP	32 (23-39)	BNT162b2	All infections	14	67.4 (46.3–80.9) weeks	0-4	83.8 (73.6–90.5)	Delta	
Nasreen/Canada _preprint	TNCC	991/351,540	GP	≥16	BNT162b2	Symptomatic	21	61.0 (51.0–70.0)	14	85.0 (59.0–94.0)	Delta	
			GP	≥16	mRNA-1273	Symptomatic	21	70.0 (52.0–81.0)	NA	NA	Delta	
			GP	≥16	ChAdOx1	Symptomatic	21	70.0 (46.0–83.0)	NA	NA	Delta	
Tang/Qatar	TNCC	1,959/1,959	GP	31 (24-37)	BNT162b2/	All infections	14	70.5 (55.2–80.6)	14	63.3 (55.7–69.6)	Delta	

<i>_preprint</i>											
mRNA-1273											
		1,830/1,830	GP	31 (24-37)	BNT162b2	All infections	14	65.5 (40.9–79.9)	14	59.6 (50.7–66.9)	Delta
		1,666/1,666	GP	31 (24-37)	mRNA-1273	All infections	14	79.7 (60.8–89.5)	14	86.1 (78.0–91.3)	Delta
Pramod/India	TNCC	360/360	HCWs	34 (28-43)	ChAdOx1-S	All infections	21	49.0 (17.0–68.0)	14	54.0 (27.0–71.0)	Delta
<i>_preprint</i>											
Pouwels/UK	Cohort	358,983 (total)	GP	≥18	BNT162b2	All infections	21	57.0 (50.0–63.0)	14	80.0 (77.0–83.0)	Delta
<i>_preprint</i>											
			GP	≥18	ChAdOx1	All infections	21	46.0 (35.0–55.0)	14	67.0 (62.0–71.0)	Delta
			GP	18-64	mRNA-1273	All infections	21	75.0 (64.0–83.0)	NA	NA	Delta

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; TNCC, test-negative case-control; LTCH, long term care homes; GP, general population; Day\_1, days after the 1<sup>st</sup> dose; Day\_2, days after the 2<sup>nd</sup> dose; RCT, randomized controlled trial; CI, confidence interval.

<sup>1</sup> Median age (interquartile range)